| Title |
Ilgo veikimo antipsichotikai pirmos eilės gydymui / |
| Translation of Title |
Long-acting injectable antipsychotics as first-line treatment. |
| Authors |
Sipavičiūtė, Agnė |
| Full Text |
|
| Is Part of |
Medicinos mokslai = Journal of medical sciences.. Kėdainiai : VšĮ Lietuvos sveikatos mokslinių tyrimų centras. 2021, t. 9, Nr. 3, p. 94-99.. eISSN 2345-0592 |
| Keywords [eng] |
antipsychotic long-acting injections ; depot antipsychotics ; long-acting injectable antipsychotics ; schizophrenia ; early psychosis ; first episode psychosis. |
| Abstract [eng] |
Non-adherence remains a significant problem in schizophrenia treatment. Discontinuation of treatment results in relapse and thereforeleads topoor long-term prognosis. Long-acting injectable (LAI) antipsychotics (AP) are used to address non-adherence and to maintain consistent long-term treatment, which is recommended to be continued for 2-5 years. Depot APs are under prescribedand frequentlyused forpatients that are non-adherent tooral antipsychoticsand have already experienced multiple psychotic episodes. This is mostly associated with clinicians’ attitudes towards depot medication. Long-acting APs are related to lower relapse and hospitalization rates compared to oraltreatment. Therefore, LAIwould be most beneficial in early schizophrenia treatment, with the aim to avoid relapse and poor long-term prognosis.Adherence and LAI prescription rates might also be improved by enhanced patient involvement in treatment choice. |
| Published |
Kėdainiai : VšĮ Lietuvos sveikatos mokslinių tyrimų centras |
| Type |
Journal article |
| Language |
Lithuanian |
| Publication date |
2021 |
| CC license |
|
